



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/784553/2013

European Medicines Agency decision

P/0006/2014

of 22 January 2014

on the acceptance of a modification of an agreed paediatric investigation plan for telbivudine (Sebivo) (EMA-000065-PIP01-07-M04) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

P/0006/2014

of 22 January 2014

on the acceptance of a modification of an agreed paediatric investigation plan for telbivudine (Sebivo) (EMA-000065-PIP01-07-M04) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/111/2008 issued on 1 December 2008, the decision P/119/2010 issued on 9 July 2010, the decision P/203/2011 issued on 31 August 2011, and the decision P/0236/2012 issued on 22 October 2012,

Having regard to the application submitted by Novartis Europharma Limited on 13 September 2013 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 6 December 2013, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for telbivudine (Sebivo), film-coated tablet, oral solution, oral use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Novartis Europharma Limited, Wimblehurst Road, RH12 5AB – Horsham, United Kingdom.

Done at London, 22 January 2014

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/PDCO/567764/2013

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan EMA-000065-PIP01-07-M04

Scope of the application

Active substance(s):

Telbivudine

Invented name:

Sebivo

Condition(s):

Treatment of chronic hepatitis B

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Film-coated tablet

Oral solution

Route(s) of administration:

Oral use

Name / corporate name of the PIP applicant:

Novartis Europharma Limited

Information about the authorised medicinal product:

See Annex II



Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Novartis Europharma Limited submitted to the European Medicines Agency on 13 September 2013 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/111/2008 issued on 1 December 2008, the decision P/119/2010 issued on 9 July 2010, the decision P/203/2011 issued on 31 August 2011, and the P/0236/2012 issued on 22 October 2012.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 10 October 2013.

Scope of the modification

Some measures of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

London, 6 December 2013

On behalf of the Paediatric Committee
Dr Dirk Mentzer, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

1. Waiver

1.1. Condition: treatment of chronic hepatitis B

The waiver applies to:

- the paediatric population from birth to less than 2 years of age;
- for oral solution and film-coated tablet, oral use;
- on the grounds that clinical studies cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the paediatric population.

2. Paediatric Investigation Plan

2.1. Condition: treatment of chronic hepatitis B

2.1.1. Indication(s) targeted by the PIP

- Treatment of children with HBeAg-positive compensated chronic hepatitis B.
- Treatment of children with HBeAg-negative compensated chronic hepatitis B.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 years to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Film-coated tablet for oral use.

Oral solution.

2.1.4. Measures

Area	Number of measures	Description
Quality	1	Measure 1: Development of an age appropriate formulation for oral use
Non-clinical	2	Measure 2: A 20-day oral (gavage) neonatal and juvenile development dose range-finding study in rats Measure 3: A 10-week oral (gavage) study in juvenile rats to evaluate telbivudine effect on the postnatal development

Clinical	3	Measure 4: Open-Label, single-dose study in children and adolescents with Chronic Hepatitis B Virus Infection from 2 to less than 18 years of age to evaluate pharmacokinetics, safety and tolerability of telbivudine Measure 5: Randomised, double-blind, placebo-controlled, multi-centre study to evaluate pharmacokinetics, efficacy and safety of telbivudine in children and adolescents aged from 2 to less than 18 years with compensated HBeAg-positive and HBeAg-negative chronic hepatitis B virus infection Measure 6: A cross-sectional, multi-center retrospective data collection study in Western and Asian countries in children and adolescents with chronic hepatitis B virus infection in patients aged from 2-to less than 18 year
----------	---	---

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	No.
Date of completion of the paediatric investigation plan:	By March 2018.
Deferral for one or more measures contained in the paediatric investigation plan:	Yes.

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of chronic hepatitis B

Authorised indication(s):

- Sebivo is indicated for the treatment of chronic hepatitis B in adult patients with compensated liver disease and evidence of viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis.
- Initiation of Sebivo treatment should only be considered when the use of an alternative antiviral agent with a higher genetic barrier to resistance is not available or appropriate.

Authorised pharmaceutical form(s):

Film-coated tablet, Oral solution

Authorised route(s) of administration:

Oral use